Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04562792 · ClinicalTrials.gov registry record · Phase 2
Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia
A Phase 2 study, sponsored by Children's Mercy Hospital Kansas City.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT04562792 is a Phase 2 study that has completed, run by Children's Mercy Hospital Kansas City. The registered enrollment target is 1 participants.
The verdict
NCT04562792, a Phase 2 study, has completed, sponsored by Children's Mercy Hospital Kansas City.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
In this pilot study, eligible pediatric patients will be treated with 5 consecutive days of low dose daunorubicin. All patients who receive low dose daunorubicin will be evaluated daily for potential toxicity during those 5 days. Once the patient has received 5 doses of daunorubicin, subsequent therapy will be at the discretion of the primary oncology team.
Interventions
- DRUG Daunorubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-05-08 |
| Est. Completion | 2022-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04562792
The ClinicalTrials.gov registry entry for NCT04562792 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Mercy Hospital Kansas City, which has 184 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Daunorubicin is the first listed.
NCT04562792 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04562792 about?
NCT04562792 is a clinical study titled "Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia". In this pilot study, eligible pediatric patients will be treated with 5 consecutive days of low dose daunorubicin. All patients who receive low dose daunorubicin will be evaluated daily for potential toxicity during those 5 days. Once the patient has received 5 doses of daunorubicin, subsequent ther...
What is the current status of trial NCT04562792?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2020-05-08. Estimated completion is 2022-06-30.
What interventions are being tested in trial NCT04562792?
The interventions under investigation include: Daunorubicin (DRUG).
Who is sponsoring clinical trial NCT04562792?
This trial is sponsored by Children's Mercy Hospital Kansas City, which has 184 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.